MediciNova (MNOV) Q1 2026 earnings summary

Executive summary

• Focused on developing MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic/metabolic diseases, with a U.S. commercial focus.

• Strategy includes advancing clinical programs via investigator-sponsored trials, grants, and strategic alliances.

• Accumulated deficit reached $441.3 million as of March 31, 2026, with continued net losses expected.

Financial highlights

• Revenue was $0.2 million for Q1 2026, up from $0.0 million in Q1 2025, due to the Mayo agreement.

• Net loss for Q1 2026 was $2.6 million, an improvement from $2.9 million in Q1 2025.

• Cash and cash equivalents totaled $27.3 million as of March 31, 2026.

• Operating expenses decreased to $3.0 million in Q1 2026 from $3.2 million in Q1 2025.

• Basic and diluted net loss per share was $0.05, compared to $0.06 in Q1 2025.

Outlook and guidance

• Sufficient cash to fund operations through at least May 2027.

• Expects to incur substantial net losses for several years as development programs progress.

• Additional capital will be required to advance clinical trials and operations.